Astrazeneca PLC 6-K, filed Mar 9, 2023
Astrazeneca PLC (AZN)
6-K
2023-03-09
For: 2023-03-09
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on March 9, 2023.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Imfinzi improved EFS in resectable lung cancer
9 March 2023 07:00 GMT
Imfinzi significantly
improved event-free survival in AEGEAN
Phase III trial for patients with resectable non-small cell lung
cancer
Results showed that Imfinzi-based treatment before and after
surgery significantly increased the time patients live without
recurrence or progression events
Positive high-level results from a planned interim analysis of the
AEGEAN Phase III, placebo- controlled trial showed that treatment
with AstraZeneca's Imfinzi (durvalumab) in combination with neoadjuvant
chemotherapy before surgery and as adjuvant monotherapy after
surgery demonstrated a statistically significant and clinically
meaningful improvement in event-free survival (EFS) versus
neoadjuvant chemotherapy alone followed by surgery for patients
with resectable early-stage (IIA-IIIB) non-small cell lung cancer
(NSCLC).
Results from the final pathologic complete response
(pCR) and
major pathologic response
(mPR) analyses were consistent
with previously
announced positive
results. The
trial will continue as planned to assess key secondary endpoints
including disease-free survival (DFS) and overall survival
(OS).
Each year there are an estimated 2.2 million people diagnosed with
lung cancer globally with 80-85% of patients diagnosed with NSCLC,
the most common form of lung cancer.1-3 Approximately
25-30% of all patients with NSCLC are diagnosed early enough to
have surgery with curative intent.4-5 However,
only around 56-65% of patients with Stage II disease will survive
for five years.6 This
decreases to 41% for patients with Stage IIIA and 24% for patients
with Stage IIIB disease, reflecting a high unmet medical
need.6
John V. Heymach, MD, PhD. Professor and Chair Thoracic/Head and
Neck Medical Oncology, The University of Texas MD Anderson Cancer
Center, said: "Treating
patients early with durvalumab both before and after
surgery delivers a significant and clinically meaningful
benefit in resectable non-small cell lung cancer,
where new options are urgently needed to offer
patients the best chance of long-term survival.
The AEGEAN results provide compelling evidence that this
novel durvalumab regimen can drive improved outcomes in this
curative-intent setting."
Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca, said: "Patients
with resectable non-small cell lung cancer face unacceptably high
rates of recurrence, despite treatment with chemotherapy and
surgery. We
have shown that adding Imfinzi both before and after surgery significantly
increased the time patients live without recurrence or progression
events. We will continue to follow patients for overall
survival."
Imfinzi was
well tolerated and no new safety concerns were observed in the
neoadjuvant and adjuvant settings. Further,
adding Imfinzi to neoadjuvant
chemotherapy was
consistent with the known profile for this combination
and did
not increase complications or adverse events, or compromise
patients' ability to undergo surgery versus chemotherapy
alone.
These data will be presented at a forthcoming medical meeting and
shared with global health authorities.
AstraZeneca has a comprehensive portfolio of approved and potential
new medicines in development for patients with lung cancer. In
addition to these results, the Company is also announcing today
that Tagrisso (osimertinib)
met a secondary endpoint of OS in the ADAURA Phase III trial in
early-stage (IB, II and IIIA) epidermal growth factor
receptor-mutated (EGFRm) NSCLC after
complete tumour resection with curative intent.
Notes
Lung cancer
Lung cancer is the leading cause of cancer death among both men and
women, accounting for about one-fifth of all cancer
deaths.1 Lung
cancer is broadly split into NSCLC and small cell lung cancer
(SCLC).2 The
majority of NSCLC patients are diagnosed with advanced disease
while approximately 25-30% present with resectable disease at
diagnosis.4-5 Early-stage
lung cancer diagnoses are often only made when the cancer is found
on imaging for an unrelated condition.7-8
For patients with resectable tumours, the majority eventually
develop recurrence despite complete tumour resection and adjuvant
chemotherapy.9
AEGEAN
AEGEAN is a randomised, double-blind, multi-centre,
placebo-controlled global Phase III trial
evaluating Imfinzi as perioperative treatment for patients with
resectable Stage IIA-IIIB (Eighth Edition AJCC Cancer Staging
Manual) NSCLC, irrespective of PD-L1 expression. Perioperative
therapy includes treatment before and after surgery, also known as
neoadjuvant/adjuvant therapy. In the trial, 802 patients were
randomised to receive a 1500mg fixed dose
of Imfinzi plus chemotherapy or placebo plus
chemotherapy every three weeks for four cycles prior to surgery,
followed by Imfinzi or placebo every four weeks (for up to 12
cycles) after surgery. Patients with known EGFR or ALK genomic
tumour aberrations were excluded from the primary efficacy
analyses.
In the AEGEAN trial, the primary endpoints were pCR, defined
as no viable tumour in the resection specimen (including lymph
nodes) following neoadjuvant therapy, and EFS, defined as the time
from randomisation to an event like tumour recurrence, progression
precluding definitive surgery, or death. Key secondary endpoints
were mPR, defined as residual viable tumour of less than or equal
to 10% in the resected primary tumour following neoadjuvant
therapy, DFS, OS, safety and quality of life. The final pathologic
response analyses were performed after all patients had the
opportunity for surgery and pathology assessment per the trial
protocol. The
trial enrolled participants in 264 centres in more than 25
countries including in the US, Canada, Europe, South America and
Asia.
Imfinzi
Imfinzi (durvalumab)
is a human monoclonal antibody that binds to the PD-L1 protein and
blocks the interaction of PD-L1 with the PD-1 and CD80 proteins,
countering the tumour's immune-evading tactics and releasing the
inhibition of immune responses.
Imfinzi is
the only approved immunotherapy and the global standard of care in
the curative-intent setting of unresectable, Stage III NSCLC in
patients whose disease has not progressed after chemoradiation
therapy based on the PACIFIC Phase III trial.
Imfinzi is
also approved in the US, EU, Japan, China and many other countries
around the world for the treatment of extensive-stage SCLC based on
the CASPIAN Phase III trial. In an exploratory analysis in 2021,
updated results from the CASPIAN trial
showed Imfinzi plus chemotherapy tripled patient survival
at three years versus chemotherapy alone. Additionally, Imfinzi is
approved in combination with a short course
of Imjudo (tremelimumab) and chemotherapy for the
treatment of metastatic NSCLC in the US, EU and Japan based on the
POSEIDON Phase III trial.
In addition to its indications in lung
cancer, Imfinzi is also approved in combination with
chemotherapy in locally advanced or metastatic biliary tract cancer
in the US, EU, Japan and several other countries; in combination
with Imjudo in unresectable hepatocellular carcinoma in
the US, EU and Japan; and in previously treated patients with
advanced bladder cancer in several countries.
Since the first approval in May 2017, more than 150,000 patients
have been treated with Imfinzi.
AstraZeneca has several ongoing registrational trials focused on
testing Imfinzi in earlier stages of lung cancer, including
in resectable NSCLC (ADJUVANT BR.31) and unresectable NSCLC
(PACIFIC-2, 4, 5, 8 and 9), and in limited-stage SCLC
(ADRIATIC).
As part of a broad development programme, Imfinzi is being tested as a single treatment and in
combinations with other anti-cancer treatments for patients with
SCLC, NSCLC, bladder cancer, several gastrointestinal (GI) cancers,
ovarian cancer, endometrial cancer and other solid
tumours.
AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer to
cure through the detection and treatment of early-stage disease,
while also pushing the boundaries of science to improve outcomes in
the resistant and advanced settings. By defining new therapeutic
targets and investigating innovative approaches, the Company aims
to match medicines to the patients who can benefit
most.
The Company's comprehensive portfolio includes leading lung cancer
medicines and the next wave of innovations,
including Tagrisso and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and datopotamab
deruxtecan in collaboration with Daiichi
Sankyo; Orpathys (savolitinib) in collaboration with
HUTCHMED; as well as a pipeline of potential new medicines and
combinations across diverse mechanisms of
action.
AstraZeneca is a founding member of the Lung Ambition Alliance, a
global coalition working to accelerate innovation and deliver
meaningful improvements for people with lung cancer, including and
beyond treatment.
AstraZeneca in immuno-oncology (IO)
AstraZeneca is a pioneer in introducing the concept of
immunotherapy into dedicated clinical areas of high unmet medical
need. The Company has a comprehensive and diverse IO portfolio and
pipeline anchored in immunotherapies designed to overcome evasion
of the anti-tumour immune response and stimulate the body's immune
system to attack tumours.
AstraZeneca aims to reimagine cancer care and help transform
outcomes for patients with Imfinzi as a single treatment and in combination
with Imjudo as well as other novel immunotherapies and
modalities. The Company is also exploring next-generation
immunotherapies like bispecific antibodies and therapeutics that
harness different aspects of immunity to target
cancer.
AstraZeneca is boldly pursuing an innovative clinical strategy to
bring IO-based therapies that deliver long-term survival to new
settings across a wide range of cancer types. With an extensive
clinical programme, the Company also champions the use of IO
treatment in earlier disease stages, where there is the greatest
potential for cure.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
World Health Organisation.
International Agency for Research on Cancer. Lung Fact Sheet.
Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.
Accessed March 2023.
2.
LUNGevity Foundation. Types of
Lung Cancer. Available at: https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer.
Accessed March 2023.
3.
Cheema PK, et al. Perspectives on treatment advances for
stage III locally advanced unresectable non-small-cell lung
cancer. Curr Oncol. 2019;26(1):37-42.
4.
Cagle PT, et al. Lung Cancer Biomarkers: Present Status and
Future Developments. Arch Pathol Lab
Med.
2013;137(9):1191-1198.
5.
Le Chevalier T. Adjuvant Chemotherapy for
Resectable Non-Small-Cell Lung Cancer: Where is it
Going? Ann Oncol. 2010;21:vii196-198.
6.
Goldstraw P, et al. The IASLC Lung Cancer Staging Project: Proposals
for Revision of the TNM Stage Groupings in the Forthcoming (Eighth)
Edition of the TNM Classification for Lung
Cancer. J Thorac
Oncol.
2016;11(1):39-51.
7.
Sethi S, et al. Incidental Nodule Management - Should There Be a
Formal Process? J Thorac
Onc.
2016:8;S494-S497.
8.
LUNGevity Foundation. Screening
and Early Detection. Available at: https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection. Accessed
March 2023.
9.
Pignon JP, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled
Analysis by the LACE Collaborative Group. J Clin
Oncol. 2008;26(21):3552-3559.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
09 March 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|